Eight enteric-coated 50 mg diclofenac sodium tablet formulations marketed in Saudi Arabia: in vitro quality evaluation

Muhammad M. Hammami1,2*, Rajaa F. Hussein1, Reem AlSwayeh1 and Syed N. Alvi1

Abstract

Objective: To evaluate in vitro quality of enteric-coated 50 mg diclofenac sodium tablet formulations on Saudi market.

Results: A reference and seven generic (G1-7) formulations were commercially available in December 2019/January 2020 and were assessed within 25–75% of manufacture-expiration period. Weight variation (range as% difference from mean, n=20), active substance content (ASC, mean (SD) as% difference from label, n=20), hardness (mean (SD), n=10), and friability (% weight loss, n=20) were 97–103%, 102.0% (3.4%), 15.4 (1.1) kg, and 0.24%, respectively, for the reference. For G2-7, they were ≤±5%, 98.6% (4.0%) to 109.9% (1.8%), 11.9 (0.9) to 18.3 (0.8) kg, and ≤0.00 to 0.75%, respectively. G1 ASC, hardness, and friability were 111.3% (1.7%), 20.1 (1.7) kg, and 1.10%, respectively. Disintegration time (n=6) and dissolution profile (n=8) were also determined. No formulation disintegrated or released >0.1% of label ASC in 0.1 N HCl for 2 h. The reference disintegrated in 15:00 minutes and released a mean (range) of 100% (99–103%) of label ASC by 45 min in phosphate buffer (pH=6.8). G1-7 disintegrated in 8:53 to 20:37 minutes and released 81% (69–90%) (G1) to 109%. Except for borderline performance of G1, all formulations passed in vitro quality tests according to United States Pharmacopoeia.

Keywords: Diclofenac sodium tablet, In-vitro quality, Saudi Arabia, Dissolution profile, Immediate-release, Generic formulations

Introduction

Quality generic drug products save money and improve accessibility to health care [1]. However, lay people [2] and healthcare workers [3] not infrequently question the quality of marketed generic drug products, resulting in their suboptimal use. Although generic products must pass bioequivalence testing before entering the Saudi market [4], ongoing assessment is essential to ensure that the desired quality is maintained post-marketing.

We have conducted pre-marketing [5–12] and post-marketing [13] bioequivalence studies of several drug products in Saudi Arabia. However, increasing emphasis is being placed on in vitro physiochemical quality testing [14–16] because it does not involve human subjects and have lower cost.

Diclofenac (as sodium or potassium salt) belongs to the non-steroidal anti-inflammatory drug group [17] and is one of the widely manufactured and marketed drugs in Saudi Arabia; more than 30 formulations are listed on the Saudi formulary [4]. Further, three of diclofenac products were among the top four drugs sold in Saudi Arabia in the period of 2010 to 2015 [18].

Few studies have examined in vitro quality of marketed diclofenac sodium formulations [19–23]. Some did...
not include a reference formulation [22, 23], two identified inferior products [19, 21], all used ultraviolet spectrophotometer for drug level analysis rather than high performance liquid chromatography (HPLC), and none included products from the Saudi market.

The aim of this study was to evaluate in vitro quality of enteric-coated 50 mg diclofenac sodium tablet formulations that are commercially available on the Saudi market.

Main text

Drugs and chemicals

All single-drug tablet formulations of 50 mg diclofenac sodium that were commercially available in retail pharmacies in Riyadh, Saudi Arabia during the period December 2019/January 2020 and were within 25%–75% of their manufacture-expiration period were included in the study. Label information of the included formulations (a reference and seven generic (G1 to G7) formulations) is presented in (Additional file 1: Table S1, Label information). Six other generic formulations were listed on the Saudi Formulary [4] but were not commercially available and were not included in the study.

Diclofenac sodium standard was purchased from Sigma-Aldrich (St Louis, MO, USA), HPLC grade acetonitrile and methanol from Fisher Scientific Co. (Loughborough, UK), disodium hydrogen phosphate from Fluka (Buchs, Switzerland), potassium phosphate monobasic and glacial acetic acid from Fisher Chemical (Fair Lawn, New Jersey, USA), and hydrochloric acid (HCl) from Merck (Darmstadt, F.R. Germany).

Instruments

HPLC-dissolution system (Waters Associates, Inc. Milford, MA, USA) consisted of Waters 2690D Separation Module with eight-needle dissolution dispenser, Waters Transfer Module with eight syringes, one dissolution test bath (Hanson Research SR8-Plus, USP dissolution apparatus II (paddle)), eight Uni-Probes, and Waters 996 Photodiode array detector set at 276 nm. Other instruments used included an electronic balance (Model AG 204, Mettler Toledo, Greifensee, Switzerland), as well as Microprocessor Disintegration Test Apparatus (Model SSE-731), Microprocessor Friability Apparatus (Model SSE-710), and Digital Tablet Hardness Tester (Model SSE-DIGIT AB-SPV), all from Sunshine Scientific Equipment, Delhi, India.

Sample preparation and HPLC assay

A stock solution of diclofenac sodium (1000 µg/ml) was prepared in methanol and stored at −20°C. It was diluted in a phosphate buffer (pH 6.8 ± 0.05) composed of 0.05 M disodium hydrogen phosphate and 0.05 M potassium dihydrogen phosphate (50:50, v:v) to produce standard curve (0.1, 0.5, 1.0, 5.0, 10.0, 20.0, 40.0, 60.0 and 80.0 µg/ml) and quality control (1.5, 7.5, 15, and 50 µg/ml) samples. This phosphate buffer was also used for disintegration and dissolution tests and for determining active substance content (ASC). A standard curve and three sets of quality control samples were used in each run. The HPLC assay uses liquid–liquid extraction and naproxen as an internal standard, and is linear (R² ≥ 0.998) in the range 0.1–80.0 µg/ml [24]. It was used to determine ASC in tablets and the dissolution profile. No interference from tablet’s excipients was observed.

Quality control tests and calculations

Weight variation test: 20 randomly-selected units of each formulation were examined. Mean (SD) was calculated and% deviation of individual unit weight from mean weight of the formulation was determined.

Friability test: 20 randomly-selected units of each formulation were examined. They were weighted, placed in the friabilator (25 revolutions/minute for 4 min), dedusted and weighted again, and friability was determined as% weight loss.

Hardness test: 10 randomly-selected units of each formulation were examined. Mean (SD) required pressure to break diametrically placed tablets was determined.

ASC test: 20 randomly-selected units of each formulation were examined. Tablets were individually crushed using mortar, dissolved in 100 ml methanol, filtered with a syringe using 0.2 µm filter, diluted with 9.0 ml phosphate buffer, and 100 µl was injected in the HPLC system. Mean (SD) content in mg and percent deviation of individual units from label were determined.

Disintegration test: 6 randomly-selected units of each formulation were examined using 0.1 N HCl for 2 h followed by phosphate buffer (pH 6.8) as disintegration medium. The basket rack was placed in a 1000 ml vessel containing 900 ml disintegration medium maintained at 37±2 °C with the test unit remaining 1.5 cm below the surface of the liquid on their upward movement and above 2.5 cm from the bottom of the beaker in their downward movement. The basket rack moved up and down (5–6 cm) at a frequency of 31 cycles per minute. Range of disintegration time (time to no particle on the basket) was determined.

Dissolution test: 8 randomly-selected units of each formulation were examined using 0.1 N HCl for 2 h followed by phosphate buffer (pH 6.8) as dissolution medium (900 ml), one unite in each vessel, a stirring rate of 50±1 rpm, and a temperature of 37±0.5 °C. The test ended with a stirring rate of 250 rpm for 15 min (infinity). A sample of 1.0 ml was withdrawn from a zone midway between the surface of the dissolution medium and the
Results

Main results are summarized in the Table 1. Mean weight of the eight formulations ranged from 192.5 (3.5) to 283.6 (4.0) mg. Weight range was 97–103% of mean weight for reference formulation and within ±5% for all 7 generic formulations.

Mean (SD) ASC and percent difference from label (50 mg) for the reference formulation were 51.0 (1.7) mg and 102.0% (3.4), respectively. All generic formulations but G1 had a mean ASC between 90 and 110% of label. G1 had mean (SD) ASC and percent difference of 55.7 (0.9) mg and 111.3% (1.7), respectively.

The reference formulation had a mean (SD) hardness of 15.4 (1.1) kg and lost 0.24% of its weight during friability testing. All generic formulations but G1 passed the hardness test (optimum 10–20 kg) and had a friability of ≤ 1%. G1 had borderline hardness and friability of 20.1 (1.7) and 1.10%, respectively.

Although not all formulations were labeled as enteric-coated, none disintegrated in 0.1 N HCl for 2 h. On the other hand, phosphate buffer (pH 6.8) disintegration time of the reference formulation was 15.00 min:seconds; and all generic formulations disintegrated in less than 21 min.

Table 1 In-vitro quality of a reference and seven generic enteric-coated 50 mg diclofenac sodium tablet formulations available on the Saudi market

| Code | Weight n = 20 | Active substance content^b n = 20 | Hardness^c n = 10 | Friability^d n = 20 | Disintegration^e (phosphate buffer) n = 6 | Dissolution^f (phosphate buffer) n = 8 |
|------|---------------|-----------------------------------|-------------------|---------------------|----------------------------------------|----------------------------------------|
|      | Mean (SD) mg  | Range% from mean                  | Mean (SD) mg      | Mean (SD) % of label | Mean (SD) kg                           | %Loss                                  | Range Minute: second                  | Mean (range) release at 45 min% of label |
| R    | 212.9 (3.6)   | 97–103                            | 51.0 (1.7)        | 102.0 (3.4)         | 15.4 (1.1)                            | 0.24                                   | 15:00–15:00                            | 100 (99–103)                     |
| G1   | 203.7 (3.0)   | 97–102                            | 55.7 (0.9)        | 111.3 (1.7)         | 20.1 (1.7)                            | 1.10                                   | 14:09–14:09                            | 81 (69–90)                        |
| G2   | 208.9 (4.3)   | 95–103                            | 53.8 (2.0)        | 107.6 (4.0)         | 16.6 (1.2)                            | 0.00                                   | 17:23–19:19                            | 106 (102–109)                    |
| G3   | 192.5 (3.5)   | 96–103                            | 49.3 (2.0)        | 98.6 (4.0)          | 12.8 (0.4)                            | 0.00                                   | 13:29–13:29                            | 101 (94–113)                     |
| G4   | 283.6 (4.0)   | 97–103                            | 50.9 (1.7)        | 101.9 (3.4)         | 11.9 (0.9)                            | 0.16                                   | 20:37–20:37                            | 108 (102–112)                    |
| G5   | 232.1 (3.3)   | 98–103                            | 51.7 (2.2)        | 103.3 (4.4)         | 16.8 (1.3)                            | 0.00                                   | 18:00–18:00                            | 102 (101–103)                    |
| G6   | 243.9 (2.2)   | 99–103                            | 54.9 (0.9)        | 109.9 (1.8)         | 18.3 (0.8)                            | 0.75                                   | 9:00–9:00                              | 109 (107–112)                    |
| G7   | 219.9 (2.8)   | 98–102                            | 52.0 (2.0)        | 104.0 (4.0)         | 14.4 (0.7)                            | 0.20                                   | 8:53–8:53                              | 104 (100–107)                    |

* Acceptable variation limits < ±7.5% for tablets ≤ 80 and < 250 mg and < ±5% for tablets ≥ 250 mg; to pass, no more than 2/20 tablet differ by more than the percentage permitted and no one tablet differ by more than the double the percentage. ^ Acceptable limits, mean content 90–110% of label. °Optimum hardness for coated tablets 10–20 kg. †Acceptable limit ≤ 1%. ‡None disintegrated in 0.1 N HCl for 2 h. Acceptable limits, no disintegration in 0.1 N HCl for 2 h and complete disintegration in phosphate buffer (pH 6.8) within 60 min. ‡0 to 0.1% release was observed in 0.1 N HCl for 2 h. Acceptable limits, release of ≤ 10% of label in 0.1 N HCl and ≥ 75% in phosphate buffer (pH 6.8).

(See figure on next page.)

Fig. 1 Dissolution profiles of a reference and seven generic enteric-coated 50 mg diclofenac sodium tablet formulations available on the Saudi market, R, reference, G1 to G7, generic formulations. Eight units of each formulation were studied. Mean (SD) amount of drug released at the specified times are shown on the left axis (continuous line) and percent of label amount released on the right axis (interrupted line). Time 0 min indicates amount released after 120 min in 0.1 N HCl. Other times indicate amount released in phosphate buffer (pH 6.8). Time 105 min indicates amount released with a stirring rate of 250 rpm for 15 min (infinity), otherwise, stirring rate was 50± 1 rpm, using USP dissolution apparatus type II (paddle apparatus) and a temperature of 37± 0.5 °C. Formulations’ label details are available in Additional file 1, Label information.
gumming, capping or odd erosion pattern, sticking, air bubbles, or particles adhering to vessel or apparatus shaft was observed throughout the dissolution testing. In 0.1 N HCL for 2 h, G1 released 0.1% of its label ASC; the other formulations released 0.00%.

Discussion
We evaluated in vitro quality of a reference and 7 generic formulations of 50 mg diclofenac sodium enteric-coated tablet that were commercially available on the Saudi market. Except for borderline performance of one generic formulation (G1), all formulations passed in vitro quality tests according to United States Pharmacopoeia [25]. Namely, weight variation of ≤±7.5% from mean weight for tablets ≤80 and < 250 mg and ≤±5% for tablets ≥250 mg; mean ASC between 90 and 110% of label; ≤1% friability weight loss; no disintegration in 0.1 N HCl (2 h) and complete disintegration in phosphate buffer within 60 min; and release of ≤10% of content in 0.1 HCl (2 h) and ≥80% within 45 min in phosphate buffer (each of 6 unites individually, or mean of 12 unites). Using stricter criteria, G1, G2, and G6 would fail the ASC test [26].

Our results on the reference formulation are consistent with the literature. Three studies that included the reference formulation (although from different manufacturing sites) found, respectively, that it has a mean weight of 216, 252, and 222 mg; ASC of 98.2%, 99.4%, and 99.3% compared to label; friability of 0.15%, 0.013%, and 0.82%; no disintegration in 0.1 N HCl, disintegration time of about 12, 22, and 51 min in phosphate buffer, and 50% content release in 20, 18.1, and not reported minutes [19–21].

As illustrated in case of G1, timely disintegration does not necessarily imply adequate dissolution. On the other hand, the disintegration apparatus mechanical force is probably lower than the destructive force of the gastrointestinal tract, so especially for enteric-coated products, potential in vivo disintegration in the stomach may not be necessarily detected in vitro. Because the typical paddle dissolution apparatus delivers even milder force, it is important to conduct disintegration testing despite having acceptable dissolution test results [27].

Although most commercially available generic formulations of diclofenac sodium tablets have been found to be of acceptable in vitro quality [19, 20, 22, 23], one of the three generic formulations in one study [19] inappropriately disintegrated in acidic medium, and 3 of four generic formulations in another study [21] released less than 60% at 45 min in phosphate buffer. In the current study, one of seven generic formulations had an ASC, friability, and hardness just beyond the acceptable limits and did not quite pass dissolution testing. The results indicate the importance of on-going surveillance of marketed formulations. In-vitro testing avoids exposing humans to drugs and is time and money saving, and has been proposed as replacement of in vivo bioequivalence testing under certain circumstances [28].

Study strengths
This study is unique in examining a relatively large number of formulations, including a reference formulation, and using multiple-point dissolution curve rather than single points comparisons. It also used HPLC with the advantage of being able to separate diclofenac from potential interferences from formulation matrix/dissolution medium and detect drug degradation.

Study limitations
We may have missed some diclofenac sodium 50 mg tablet formulations available on the Saudi market. Indeed, six formulations listed on the Saudi Formulary were not available in Riyadh pharmacies at the time of the study. However, since Riyadh is the capital of Saudi Arabia, we believe that we covered the most commonly used formulations. Our results do not apply to other diclofenac formulations (different strength, extended release) or to diclofenac potassium formulations. Finally, failing an in vitro test may be related to test performance rather than formulation performance, which is not likely in our study since reference formulation didn’t fail any test and several generic formulations passed.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13104-020-05270-4.

Abbreviations
ASC: Active substance content; G: Generic formulation; HCL: Hydrochloric acid; HPLC: High performance liquid chromatography; R: Reference formulation; SD: Standard deviation.

Acknowledgements
Not applicable.

Authors’ contributions
MH designed the study, performed data analysis, and wrote the manuscript. RFH, RAS, and SNA performed the experiments, co-analyzed data, and co-wrote the manuscript. All authors agree to be accountable for all aspects of the work and approved the final version of the manuscript. All authors read and approved the final manuscript.
Funding
Not applicable.

Availability of data and materials
Additional data are available in (Additional file 1: Table S1, Label information).
Raw data are available from the corresponding author upon request.

Ethics approval and consent to participate
This study was conducted after approval of the Research Advisory Council of the King Faisal Specialist Hospital and Research Center. The study did not involve human or animal subjects.

Consent to publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Clinical Studies and Empirical Ethics Department, King Faisal Specialist Hospi-
tal and Research Centre, MBC 03, PO Box # 3354, Riyadh 11211, Saudi Arabia.
2 AlFaisal University College of Medicine, Riyadh, Saudi Arabia.

References
1. Anonymous (2015). Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. WHO Regional Office for Europe. https://apps.who.int/iris/handl e/10665/159405. Accessed 16 July 2020.
2. Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;13:173. https://doi.org/10.1186/s12916-015-0415-3.
3. Toverud E-L, Hartmann K, Håkonsen H. A systematic review of physicians’ and pharmacists’ perspectives on generic drug use: what are the global challenges? Appl Health Econ Health Policy. 2015;13(Suppl 1):35–45. https://doi.org/10.1007/s40258-014-0145-2.
4. Saudi Food and Drug Authority. https://old.sfda.gov.sa/en/drug/search/Pages/default.aspx. Accessed 14 July 2020.
5. Locker M, Al-Dghiter S, AlGaai E, Yusuf A, Hammami MM. Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. Biopharm Drug Dispos. 2005;26(3):117–20.
6. Locker M, Al-Dghiter S, AlGaai E, Hammami MM. Bioequivalence of two oral formulations of gatifloxacin tablets in healthy male volunteers. J Appl Res. 2005;5(1):73–9.
7. AlGaai E, Locker M, Al-Dghiter S, Hammami MM. Bioequivalence evaluation of two formulations of fluconazole 150 mg capsules in healthy Arab men. Biopharm Drug Dispos. 2005;26(4):143–6.
8. AlGaai E, Al-Dghiter S, Locker M, Hammami MM. Bioequivalence study of two amoxicillin formulation. Drug Res. 2006;56(1):740–3.
9. Yusuf A, Al Gaai E, Hammami MM. Bioequivalence evaluation of two rosiglitazone tablet formulations. Drug Res. 2006;56(1):740–3.
10. Hussein R, Locker M, Yusuf A, AlGaai E, Abdelgaleel A, Hammami MM. Bioequivalence assessment of two domperidone tablet formulations. Drug Res. 2007;57(2):101–5.
11. Hussein RF, Locker M, Hammami MM. Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers. Drug Res. 2007;57(4):192–5.
12. AlHawari S, AlGaai E, Yusuf A, Abdelgaleel A, Hammami MM. Bio-equivalence study of two metformin tablet formulations. Drug Res. 2007;57(4):192–5.
13. Hammami MM, De Padua SJS, Hussein R, Al Gaai E, Khodri NA, Al-Swayer R, Alvi SN, Binhashim N. Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs. BMC Pharmacol Toxicol. 2017(18):78. https://doi.org/10.1186/s40360-017-0182-1.
14. FDA Center for Drug Evaluation and Research. Guidance for the industry: dissolution testing of immediate release solid oral dosage forms. Rockville, MD, 1997. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dissolution-testing-immediate-release-solid-oral-dosage-forms. Accessed 16 July 2020.
15. EMA Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. London, 2010. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 16 July 2020.
16. WHO Technical Report Series. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. 2006. No. 937. https://extranet.who.int/prequal/ Accessed 16 July 2020.
17. Skoutakis VA, Carter CA, Mickel TR, et al. Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intell Clin Pharm. 1988;22(11):850–9. https://doi.org/10.1177/106002808802201102.
18. Alkhamees OA, AlNemer KA, Maneea BW, AlSugair FA, AlEnizi BH, Alharf AA. Top 10 most used drugs in the Kingdom of Saudi Arabia 2010–2015. Saudi Pharm J. 2018;26(2):211–6. https://doi.org/10.1016/j. sjps.2017.12.009.
19. Almarzouki A, Omar K, Elmajri M, Alsaadi M. Comparative evaluation of different brands of enteric-coated diclofenac sodium tablets. UPSR. 2015;6(9):3829–35.
20. Giri TK, Parveen N, Thakur D, Tripathi DK. In vitro Evaluation of commercially available enteric coated tablet containing diclofenac sodium. Int J Res Pharm Biomed Sci. 2012;3(2):875–81.
21. Ayorinde JO, Odeniya MA, Itiola AO. Evaluation of pharmaceutical and chemical equivalence of selected brands of diclofenac sodium. East Cent Afr J Pharm Sci. 2012;15:3–9.
22. Sultana T, Sohel MD, Kawser MH, Banoo R. In vitro dissolution study and assay of diclofenac sodium from marketed solid dosage form in Bangladesh. J Bioanal Biomed. 2017;9(1):118–22. https://doi.org/10.1186/s40360-017-0000-0.
23. Joseph NM, Degu M, Palani S. Comparative quality evaluation of six brands of enteric coated diclofenac sodium tablets marketed in Addis Ababa. UPSR. 2017;8(12):5386–91.
24. Hussein R, Hammami MM. Fully validated diclofenac HPLC assay. CAJU. 2009;8(2):124–9.
25. Pharmacopoeia online. USP32. http://www.usp.org/cgi-bin/pub/pub-data/s/32270/usp32ntf77e_m24070.html. Accessed 16 July 2020.
26. Ninth Edition of The International Pharmacopoeia, published in 2019. WHO https://apps.who.int/phtinfo/en/p/doctf/archangelofindinginformation.html. Accessed 16 July 2020.
27. Al-Gousous J, Langguth P. Oral solid dosage form disintegration testing-the forgotten test. J Pharm Sci. 2010;99(2):124–9.
28. Anand O, Yu LX, Conner DP, Davit BM. Dissolution testing for generic drugs: an FDA perspective. AAPS J. 2011;13(3):328–35. https://doi.org/10.1208/s12248-011-9272-y. (Epub 2011 Apr 9).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.